A Phase 2 interventional study of AXS-05 and Bupropion SR in Smoking Cessation, Smoking, Cigarette and Nicotine Dependence, sponsored by James Davis. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-19.
Sponsored by James Davis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 920 studies in Smoking Cessation with a site in United States — 98 open to participants now, 126 under way, 7 of them phase 3. Smoking Cessation · United States.
Among the 920 studies in Smoking Cessation with a site in United States, this one is the 626th largest by enrollment of the 872 interventional ones that give a count, is one of 51 that started in 2018, is one of 105 in phase 2, and was the 569th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →98 of the 920 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
920 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 138 · Phase 3 91 · Phase 4 99
First in 1996; this study’s year is marked. 51 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 149 across the 872 interventional studies, 200 across the 45 observational. Of the 756 that completed or were terminated, 376 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 920 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with James Davis as lead sponsor.
James Davis has 1 study filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
55 of the studies in Smoking Cessation with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT00591175Memorial Sloan Kettering Cancer CenterA Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 55 to your calendar (.ics) → With an account.
Among the 920 studies in Smoking Cessation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.
This study aims to investigate the potential efficacy of a combination of two FDA-approved agents, sustained release (SR) Bupropion (BUP) and immediate release (IR) Dextromethorphan (DXM), for the purpose of smoking cessation treatment. DXM, a widely used over-the-counter cough suppressant, is a nicotine receptor antagonist. In fact, studies by Duke's Center for Smoking Cessation (CSC) have shown that administration of DXM leads to a decrease in self-administration of nicotine in nicotine-dependent rats. DXM, however, has not been studied in humans. DXM, when taken alone, is not expected to be useful for treating nicotine dependence in humans given DXM rapidly metabolizes in humans via CYP2D6. As a result, therapeutic concentrations needed to bind to nicotine receptors are not obtained. Therapeutic concentrations of DXM are required, therefore, to allow DXM to bind to nicotine receptors and act as a nicotine antagonist. In order to attain therapeutic concentrations of DXM a metabolism inhibitor must be introduced. BUP is a well-known FDA approved smoking cessation medication that has been shown to inhibit the metabolism of DXM. When BUP is co-administered with DXM to healthy volunteers, a significant increase in DXM plasma levels is observed.
Currently, Axsome Therapeutics Inc. (Axsome) is developing and testing an oral fixed-dose combination of IR DXM with SR BUP to achieve therapeutic concentrations of DXM. This investigational drug has been named AXS-05. Axsome has found AXS-05 to be generally safe and well-tolerated in three Phase 1 studies. The adverse event profile of AXS-05 was similar to that of BUP alone.
Given the distinct mechanisms by which BUP and DXM interact, it is hoped that combining DXM and BUP will prove more efficacious than either drug administered alone for the purpose of tobacco use treatment in humans.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Drug: AXS-05
Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Drug: Bupropion SR
Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Also known as: Bupropion/dextromethorphan
Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Also known as: Wellbutrin SR, Zyban SR
Change in Smoking Intensity
Smoking intensity refers to the number of cigarettes smoked per day.
Time frame: Baseline (V1), 3-Week Follow-Up Visit (V4)
Percentage of Participants Who Experienced a More Than 50% Reduction in Expired Carbon Monoxide (CO) Levels
A biochemical marker of smoking intensity.
Time frame: Baseline (V1), 3-Week Follow-Up Visit (V4)
Change in Smoking Behavior
7-day point prevalence smoking abstinence. Measured by composite self-report diaries and biochemically confirmed via expired CO and salivary cotinine.
Time frame: 3-Week Follow-Up Visit (V4), 4-Week Follow-Up Visit (V5)
Medication Adherence
Medication adherence is measured by composite self-reported diaries.
Time frame: Baseline (V1), 3-Week Follow-Up Visit (V4)
Medication Tolerance by Self-Reported Side Effects
Number of participants who scored 3 or higher on a 7-point Likert scale ranking severity of side effects (1-2 mild; 3-5 moderate; 6-7 severe).
Time frame: Baseline (V1), 3-Week Follow-Up Visit (V4)
Medication Tolerance by Serious Adverse Events
Measured by FDA reporting guidelines on adverse event or serious adverse event designation.
Time frame: Baseline (V1), 4-Week Follow-Up Visit (V5)
Urinary Levels of Dextromethorphan
Measured via Urinary Dextromethorphan testing.
Time frame: 3-Week Follow-Up Visit (V4)
| Milestone | AXS-05 | Bupropion SR |
|---|---|---|
| Started | 31 | 27 |
| Completed | 25 | 23 |
| Not completed | 6 | 4 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Pi withdrawal | 1 | 3 |
Smoking intensity refers to the number of cigarettes smoked per day.
| change in cigarettes per day | AXS-05 | Bupropion SR |
|---|---|---|
| Change in Smoking Intensity | -8.49 ± 0.37 | -6.79 ± 0.39 |
7-day point prevalence smoking abstinence. Measured by composite self-report diaries and biochemically confirmed via expired CO and salivary cotinine.
| Participants | AXS-05 | Bupropion SR |
|---|---|---|
| Change in Smoking Behavior | 16 | 12 |
Medication adherence is measured by composite self-reported diaries.
| percentage of adherence | AXS-05 | Bupropion SR |
|---|---|---|
| Medication Adherence | 97.08 ± 5.97 | 96.60 ± 5.27 |
Number of participants who scored 3 or higher on a 7-point Likert scale ranking severity of side effects (1-2 mild; 3-5 moderate; 6-7 severe).
| Participants | AXS-05 | Bupropion SR |
|---|---|---|
| Medication Tolerance by Self-Reported Side Effects | 7 | 5 |
Measured by FDA reporting guidelines on adverse event or serious adverse event designation.
| Participants | AXS-05 | Bupropion SR |
|---|---|---|
| Medication Tolerance by Serious Adverse Events | 0 | 0 |
Measured via Urinary Dextromethorphan testing.
| ng/mL | AXS-05 | Bupropion SR |
|---|---|---|
| Urinary Levels of Dextromethorphan | 1902.1 ± 1304.4 | — |
A biochemical marker of smoking intensity.
| percentage of participants | AXS-05 | Bupropion SR |
|---|---|---|
| Percentage of Participants Who Experienced a More Than 50% Reduction in Expired Carbon Monoxide (CO) Levels | 52.0 | 30.4 |
Collected over Approximately four weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AXS-05 | 0/31 (0%) | 2/31 (6.5%) | 4/31 (12.9%) |
| Bupropion SR | 0/27 (0%) | 1/27 (3.7%) | 8/27 (29.6%) |
| Event | AXS-05 | Bupropion SR |
|---|---|---|
| StrokeNervous system disorders | 0/31 | 1/27 |
| Urinary Tract InfectionInfections and infestations | 1/31 | 0/27 |
| Broken JawInjury, poisoning and procedural complications | 1/31 | 0/27 |
| Event | AXS-05 | Bupropion SR |
|---|---|---|
| Dry MouthGastrointestinal disorders | 2/31 | 3/27 |
| HeadacheNervous system disorders | 0/31 | 2/27 |
| Insomnia/Sleep DisturbancePsychiatric disorders | 2/31 | 2/27 |
| Abnormal/Vivid DreamsPsychiatric disorders | 0/31 | 1/27 |
| Age, Categorical(Participants) | AXS-05 | Bupropion SR | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 27 | 26 | 53 |
| >=65 years | 4 | 1 | 5 |
| Age, Continuous(years) | AXS-05 | Bupropion SR | Total |
|---|---|---|---|
| Mean | 50.03 ± 13.61 | 46.48 ± 11.34 | 48.38 ± 12.62 |
| Sex: Female, Male(Participants) | AXS-05 | Bupropion SR | Total |
|---|---|---|---|
| Female | 16 | 14 | 30 |
| Male | 15 | 13 | 28 |
| Ethnicity (NIH/OMB)(Participants) | AXS-05 | Bupropion SR | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 30 | 25 | 55 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AXS-05 | Bupropion SR | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 15 | 23 |
| White | 22 | 11 | 33 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | AXS-05 | Bupropion SR | Total |
|---|---|---|---|
| United States | 31 | 27 | 58 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Mar 2019, 12 months.
Results were first posted in Oct 2022, 3 years 6 months after primary completion. A results delay was requested in Mar 2020.
Of 42 non-industry phase 2 interventional studies under Smoking Cessation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 61. This study's 12 months is below that.
Counting every sponsor, half of 51 studies reached it within 35 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05